Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04112095 · ClinicalTrials.gov registry record · Phase 3
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
A Phase 3 study, sponsored by HRA Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 962
- Enrollment target
NCT04112095: Completed Phase 3 study, sponsored by HRA Pharma.
NCT04112095 is a Phase 3 study that has completed, run by HRA Pharma. The registered enrollment target is 962 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04112095, a Phase 3 study, has completed, sponsored by HRA Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 962 participants
- Enrollment target
Study Summary
This study is designed to assess whether consumers select and use norgestrel 0.075 mg, a progestin only pill for contraception, in a manner consistent with the OTC package directions in an Over-the-Counter (OTC)-like setting.
Primary Outcome
Measurement tool: interview
Interventions
- DRUG Norgestrel 0.075 mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 962 participants |
| Start Date | 2019-09-06 |
| Est. Completion | 2021-08-05 |
| Phase | Phase 3 |
What the finished NCT04112095 record still lists
NCT04112095 is an interventional study that assigns participants to a tested intervention. The registered 962 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% higher).
The record links to 0 conditions, and to 1 intervention - of which Norgestrel 0.075 mg tablets is the first listed.
NCT04112095 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04112095 about?
NCT04112095 is a clinical study titled "Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use". This study is designed to assess whether consumers select and use norgestrel 0.075 mg, a progestin only pill for contraception, in a manner consistent with the OTC package directions in an Over-the-Counter (OTC)-like setting.
What is the current status of trial NCT04112095?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 962 participants. The study started on 2019-09-06. Estimated completion is 2021-08-05.
What interventions are being tested in trial NCT04112095?
The interventions under investigation include: Norgestrel 0.075 mg tablets (DRUG).
Who is sponsoring clinical trial NCT04112095?
This trial is sponsored by HRA Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04112095's enrollment target sits among peer trials
962 330th of 2000 higher than 1,671 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
- NCT05178498 · 960 participants
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
- NCT05946629 · 960 participants · NA
SELUTION 4 De Novo Small Vessel IDE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI